Few expected it, but it happened: The UK is out of the European Union. And while this may seem like an overwhelming and confusing event, and there is risk involved, it’s manageable. First, we hedged our portfolio with a position in the ProShares Ultrashort Biotech ETF (BIS). This has helped… Read More
Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
Shares of Emergent Biosolutions (EBS), the producer of vaccines aimed at bio-terror microbe b. anthrax, fell as much as 25% on June 22, 2016. As best as we can tell, the decline in the shares is related to investor disappointment over a government contract for the production of BioThrax, the… Read More
Something is amiss in the financial markets as evidenced by their increasing volatility. And while I’m not looking to be an alarmist, my analysis of multiple technical indicators suggests that more money is coming out of stocks than going into them. Read More
As markets become more volatile, it’s worthwhile to consider ways to protect long term portfolio holdings as well as how to profit in down markets. Read More
- June 17, 2016
-
Download Issue
This company plays a pivotal role powering video tech devices. Read More
Cerus Corp. (CERS), a provider of a leading system for blood infection control, and Rollins Inc. (ROL), a global leader in pest control, may gain ground if the Zika virus creates a health emergency as the summer heats up and the effects of the spring rains and travel patterns increase… Read More
I think its time to buy the ProShares Ultra Short Biotech ETF (BIS) from $39-$42, and apply a trailing 6% sell stop. This trade is designed to preserve the portfolio’s overall value or to decrease the potential losses that may develop in individual stocks if the market hits a 5-10% correction… Read More
Calm waters can be hiding places for big sharks. This market seems to be in a steady up trend and many investors are looking to relax. But in our opinion the calm demeanor of the S & P 500 is misleading and complacent investors could be in for a nasty surprise. And as traders hit the beaches, and the Federal Reserve makes interest rate decisions in the next few days and weeks, the markets are increasingly vulnerable. Read More
It’s summertime, and on Wall Street that usually means low volume days and sluggish price movements. But Rollins (NYSE: ROL), a pest-control company, has a nifty ten-year record of summer gains. The stock has rallied 80% of the time during the summer months since 2006. A move above $29 could… Read More
- May 26, 2016
-
Download Issue
Amgen (AMGN) is well-positioned for the aging population with its osteoporosis drug Prolia ($1.5 billion in annual sales) and has the potential to increase its market share in the treatment of the condition with Romosozumab, a related drug aimed at spinal vertebral fractures in patients with osteoporosis. Romosozumab is currently… Read More